2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5575 Additional clinical benefit following avapritinib dose increase from 25 mg to 50 mg in a subset of patients with indolent systemic mastocytosis in PIONEER

Tsewang Tashi, MD, Jason Gotlib2, Deepti H. Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed3, Jens Panse4, Daniel J DeAngelo, MD, PhD5, Andreas Reiter V, MD6, Hui-Min Lin7, Ilda Bidollari, MD, MBA8, Jian Guo9, Anitha Suram10, Janet Hong11, Ben Lampson, MD, PhD12, Ivan Alvarez-Twose, MD, PhD13
1 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
2 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California, United States
3 Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom
4 Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany, University Hospital Aachen, Medical Faculty, RWTH Aachen University, Aachen, Germany
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 University Hospital Mannheim, Heidelberg University, Mannheim, Germany
7 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
8 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
9 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
10 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
11 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
12 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
13 Health Research Institute of Castilla-La Mancha (IDISCAM), Toledo, Spain, Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast), Virgen del Valle Hospital, Toledo, Spain

Introduction:

Indolent systemic mastocytosis (ISM) is a clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of cases. Patients with ISM experience symptoms of varying severity across multiple organ systems, which can impair quality of life (QoL). Avapritinib, a potent, selective KIT D816V inhibitor, is the first and only approved targeted therapy for adults with ISM. In PIONEER (NCT03731260), avapritinib significantly improved ISM-Symptom Assessment Form (ISM-SAF; ©2018 Blueprint Medicines Corporation) total symptom score (TSS) versus placebo at 24 weeks (–15.6 vs –9.2, respectively; P=0.003). Patients could continue avapritinib long-term in the open-label extension (OLE) where durable improvements in symptoms, QoL, and disease burden biomarkers were observed through 4 years of treatment. Dose increase to 50 mg once daily (QD) [henceforth 50 mg] was permitted. This analysis evaluated outcomes following dose increase to 50 mg following avapritinib 25 mg QD [henceforth 25 mg].

Methods:

PIONEER (NCT03731260) enrolled adults with moderate to severe ISM (ISM-SAF TSS ≥28 at screening). Patients who completed PIONEER Part 1 (randomized dose-finding) or Part 2 (randomized, double-blind, placebo-controlled) rolled over to Part 3 (OLE) and were treated with avapritinib for up to 5 years. In Part 3, patients receiving avapritinib 25 mg for at least 6 months were eligible to increase to 50 mg if they had an increase in symptoms and biomarkers of disease burden while on study or had KIT D816V variant allele fraction (VAF) ≥6% in peripheral blood (a specific marker of multilineage involvement of the KIT mutation) at any time on study. This analysis included patients who initiated avapritinib 25 mg + best supportive care and increased to 50 mg in Part 3.

Population pharmacokinetics (PK) were studied at 25 and 50 mg doses. Efficacy was assessed by measuring changes in symptoms (ISM-SAF), QoL (Mastocytosis Quality-of-Life Questionnaire [MC-QoL]), serum tryptase levels, and KIT D816V VAF. Efficacy outcomes were assessed 1-year post-dose increase, using the time of the dose increase as the baseline to determine additional benefit. Safety post-dose increase was also evaluated.

Results:

Overall, 74/226 patients (33%) dose increased from avapritinib 25 mg to 50 mg by September 17, 2025. In these patients, median treatment duration with avapritinib 25 mg prior to dose increase was 31.4 (range; 11.3–52.5) months. Median treatment duration post-dose increase to avapritinib 50 mg was 16.5 (range; 0.2–33.6) months. In a univariate analysis, patients who increased to 50 mg versus patients who remained on 25 mg had a higher mean ISM-SAF TSS (53.2 vs 45.6, respectively; P=0.0075) and median KIT D816V VAF (0.54% vs 0.22%, respectively; P=0.0332) at the start of avapritinib 25 mg, whereas median tryptase was not significantly different between the two groups (41.2 ng/mL vs 38.7 ng/mL, P=0.4231).

Among patients with PK samples while on 25 mg, avapritinib exposure was similar between patients who eventually dose increased (n=64) and those who did not (n=80), indicating exposure is not a predictor of dose increase. A 2-fold dose proportional increase in avapritinib exposure was observed after dose increase to 50 mg.

From time of dose increase to week 48 (~1 year), mean change in TSS was −10.6 (standard deviation [SD]; 15.7), mean percent change in MC-QoL was −27.5 (SD; 30.7), and median percent changes in serum tryptase and KIT D816V VAF were −45.6 and −38.0, respectively. The safety profile of 50 mg was similar to that of 25 mg, with no new safety concerns identified. The most commonly reported (≥5% of patients) new, recurrent, or worsening treatment-related adverse event (AE) observed at 50 mg was peripheral edema in 6 (8%) patients (all Grade 1–2). No patients discontinued treatment due to AEs while receiving 50 mg.

Conclusion:

The majority of patients with ISM derived long-term benefit from avapritinib 25 mg. In a subset of patients who increased to 50 mg after extended treatment with 25 mg, further reduction in symptoms and biomarkers of disease burden were observed post-dose increase. Avapritinib exposure at 25 mg did not predict which patients would subsequently require dose increase to 50 mg. Safety profile of avapritinib 50 mg was similar to that observed with avapritinib 25 mg, with no new safety concerns identified. In patients who dose increased, these findings support a positive benefit-risk profile for avapritinib 50 mg.

Tsewang Tashi, MD: Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Honoraria; Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Research Funding; Incyte - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)